Resveratrol as an effective adjuvant therapy in the management of rheumatoid arthritis: a clinical study
- 281 Downloads
Resveratrol (RSV), a naturally occurring polyphenol, has been found to have potent antioxidant, anti-inflammatory, and anticancer effects. Recently, RSV was reported as a new potential agent to suppress inflammation of collagen-induced arthritis in a mouse model. Nevertheless, the clinical benefits of RSV in the management of rheumatoid arthritis (RA) were not studied. This randomized controlled clinical trial aims to shed some light on the therapeutic benefits of RSV in the treatment of RA in patients with different stages of the disease activity. In this randomized controlled clinical trial, 100 RA patients (68 female, 32 male) were enrolled randomly and divided into two groups, each of 50 patients: an RSV-treated group that received a daily RSV capsule of 1 g with the conventional treatment for 3 months and a control group that just received the regular treatment. The clinical and biochemical markers of RA in both groups were assessed. It was found that the clinical markers (i.e., the 28-joint count for swelling and tenderness) and the disease activity score assessment for 28 joints were significantly lowered in the RSV-treated group. Moreover, serum levels of certain biochemical markers (i.e., C-reactive protein, erythrocyte sedimentation rate, undercarboxylated osteocalcin, matrix metalloproteinase-3, tumor necrosis factor alpha, and interleukin-6) were also significantly decreased in RSV-treated patients. The current study suggests the addition of RSV as an adjuvant to the conventional antirheumatic drugs.
KeywordsDAS28-ESR Resveratrol Rheumatoid arthritis TNF-α ucOC
The authors thank Assiut University Hospital for the help in using different analytical and research facilities.
Role of the authors
The authors had design for this study, followed-up RA patients, analyzed data, wrote the manuscript and had full authority to submit the final manuscript. Toxicological Research & Studies Center at Taibah University had only supervised the safety data for this study, with no participation on this study.
This project received financial support from Toxicological Research & Studies Center at Taibah University.
Compliance with ethical standards
Ethics approval and consent to participate
All RA patients participated in the study gave informed consent and ethical approval for the study was obtained by Institutional Review Board of the Faculty of Medicine at Assiut University.
- 2.Choy E (2012) Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) 51:v3–v11. https://doi.org/10.1093/rheumatology/kes113
- 12.Byun HS, Song JK, Kim YR, Piao L, Won M, Park KA, Choi BL, Lee H, Hong JH, Park J, Seok JH, Lee YJ, Kang SW, Hur GM (2008) Caspase-8 has an essential role in resveratrol-induced apoptosis of rheumatoid fibroblast-like synoviocytes. Rheumatology (Oxford) 47(3):301–308. https://doi.org/10.1093/rheumatology/kem368 CrossRefGoogle Scholar
- 14.Almeida L, Vaz-da-Silva M, Falcao A, Soares E, Costa R, Loureiro AI, Fernandes-Lopes C, Rocha JF, Nunes T, Wright L, Soares-da-Silva P (2009) Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol Nutr Food Res 53:S7–S15. https://doi.org/10.1002/mnfr.200800177
- 17.Anton SD, Embry C, Marsiske M, Lu X, Doss H, Leeuwenburgh C, Manini TM (2014) Safety and metabolic outcomes of resveratrol supplementation in older adults: results of a twelve-week, placebo-controlled pilot study. Exp Gerontol 57:181–187. https://doi.org/10.1016/j.exger.2014.05.015 CrossRefPubMedGoogle Scholar
- 23.Tas F, Oguz H, Argon A, Duranyildiz D, Camlica H, Yasasever V, Topuz E (2005) The value of serum levels of IL-6, TNF-alpha, and erythropoietin in metastatic malignant melanoma: serum IL-6 level is a valuable prognostic factor at least as serum LDH in advanced melanoma. Med Oncol 22(3):241–246. https://doi.org/10.1385/mo:22:3:241 CrossRefPubMedGoogle Scholar
- 24.Matsui T, Kuga Y, Kaneko A, Nishino J, Eto Y, Chiba N, Yasuda M, Saisho K, Shimada K, Tohma S (2007) Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan. Ann Rheum Dis 66(9):1221–1226. https://doi.org/10.1136/ard.2006.063834 CrossRefPubMedPubMedCentralGoogle Scholar
- 28.Wahab A, Gao K, Jia C, Zhang F, Tian G, Murtaza G, Chen J (2017) Significance of resveratrol in clinical management of chronic diseases. Molecules 22(8). https://doi.org/10.3390/molecules22081329
- 34.Heeboll S, Kreuzfeldt M, Hamilton-Dutoit S, Kjaer Poulsen M, Stodkilde-Jorgensen H, Moller HJ, Jessen N, Thorsen K, Kristina Hellberg Y, Bonlokke Pedersen S, Gronbaek H (2016) Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease. Scand J Gastroenterol 51(4):456–464. https://doi.org/10.3109/00365521.2015.1107620 CrossRefPubMedGoogle Scholar
- 35.McDermott MM, Leeuwenburgh C, Guralnik JM, Tian L, Sufit R, Zhao L, Criqui MH, Kibbe MR, Stein JH, Lloyd-Jones D, Anton SD, Polonsky TS, Gao Y, de Cabo R, Ferrucci L (2017) Effect of resveratrol on walking performance in older people with peripheral artery disease: the RESTORE randomized clinical trial. JAMA Cardiol 2(8):902–907. https://doi.org/10.1001/jamacardio.2017.0538 CrossRefPubMedPubMedCentralGoogle Scholar
- 36.McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakov O, Ford I, Capell HA, Sattar N (2004) Trial of atorvastatin in rheumatoid arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 363(9426):2015–2021. https://doi.org/10.1016/s0140-6736(04)16449-0 CrossRefPubMedGoogle Scholar
- 38.Manicourt DH, Triki R, Fukuda K, Devogelaer JP, Nagant de Deuxchaisnes C, Thonar EJ (1993) Levels of circulating tumor necrosis factor alpha and interleukin-6 in patients with rheumatoid arthritis. Relationship to serum levels of hyaluronan and antigenic keratan sulfate. Arthritis Rheum 36(4):490–499CrossRefPubMedGoogle Scholar
- 39.Brown VA, Patel KR, Viskaduraki M, Crowell JA, Perloff M, Booth TD, Vasilinin G, Sen A, Schinas AM, Piccirilli G, Brown K, Steward WP, Gescher AJ, Brenner DE (2010) Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res 70(22):9003–9011. https://doi.org/10.1158/0008-5472.can-10-2364 CrossRefPubMedPubMedCentralGoogle Scholar